Nonmelanoma Skin Cancer in Inflammatory Bowel Disease: A Review

被引：49

作者：

Long, Millie D. ^{[1
]}

Kappelman, Michael D. ^{[2
]}

Pipkin, Clare A. ^{[3
]}

机构：

[1] Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27599 USA

[2] Univ N Carolina, Dept Pediat, Div Gastroenterol & Hepatol, Chapel Hill, NC 27599 USA

[3] Duke Univ, Dept Dermatol, Durham, NC USA

来源：

INFLAMMATORY BOWEL DISEASES | 2011年 / 17卷 / 06期

基金：

美国国家卫生研究院;

关键词：

nonmelanoma skin cancer; immunosuppression; anti-TNF agents; inflammatory bowel disease; prevention; TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; CELL CARCINOMA; RISK; AZATHIOPRINE; MALIGNANCIES; THERAPY;

D O I：

10.1002/ibd.21484

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

At least 1 million new cases of nonmelanoma skin cancer (NMSC) are diagnosed in the United States each year and the incidence is increasing. A higher incidence of NMSC in organ transplant recipients on immunosuppression has been documented for some time, and recent studies indicate that patients with inflammatory bowel disease (IBD), particularly those treated with immunosuppressive medications, might also be at higher risk for this condition. In this review we summarize recent data evaluating the associations between immunomodulators, antitumor necrosis factor-a biologic agents and NMSC in patients with IBD and other autoimmune conditions such as rheumatoid arthritis. We also offer recommendations for prevention of NMSC in these populations.

引用

页码：1423 / 1427

页数：5

共 31 条

[1] AMARI W, 2009, ARTHRITIS RHEUM S10, V60, P1379
[2] Common Skin Cancers and Their Precursors
Arora, Alisha
Attwood, John
[J]. SURGICAL CLINICS OF NORTH AMERICA, 2009, 89 (03) : 703 - +
[3] Tumor necrosis factor or tumor promoting factor?
Balkwill, F
[J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (02) : 135 - 141
[4] Bolognia J., 2008, DERMATOLOGY, V1
[5] Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
Bongartz, T
Sutton, AJ
Sweeting, MJ
Buchan, I
Matteson, EL
Montori, V
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19): : 2275 - 2285
[6] Calonge N, 2009, ANN INTERN MED, V150, P188, DOI 10.7326/0003-4819-150-3-200902030-00020
[7] Chakravarty EF, 2005, J RHEUMATOL, V32, P2130
[8] EBPG EXP GROU, 2002, NEPHROL DIAL TRAN S4, V17, P31
[9] Risk of subsequent cancer following invasive or in situ squamous cell skin cancer
Efird, JT
Friedman, GD
Habel, L
Tekawa, IS
Nelson, LM
[J]. ANNALS OF EPIDEMIOLOGY, 2002, 12 (07) : 469 - 475
[10] EKBOM A, 1991, CANCER-AM CANCER SOC, V67, P2015, DOI 10.1002/1097-0142(19910401)67:7<2015::AID-CNCR2820670731>3.0.CO

← 1 2 3 4 →